NASDAQ
20.03.26 | 20:54
2,610 US-Dollar
+1,75 % +0,045
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| Di | Wells Fargo assumes coverage on Zentalis stock with $5 target | 3 | Investing.com | ||
| Di | Zentalis: Wells Fargo übernimmt Coverage mit "Equal Weight" und Kursziel von 5 US-Dollar | 2 | Investing.com Deutsch | ||
| 09.01. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.12.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.11.25 | Zentalis Pharmaceuticals GAAP EPS of -$0.37 | 3 | Seeking Alpha | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.10.25 | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| 01.10.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 142 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.09.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 196 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.07.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 214 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 168 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.05.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 237 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.04.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 239 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03.25 | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 265 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 44,100 | -0,54 % | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | ||
| VALNEVA | 4,500 | -0,44 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| NOVAVAX | 8,315 | -0,50 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,428 | +4,65 % | NurExone zeigt Flagge: Technologie rückt auf internationale Bühne | ||
| IMMUNITYBIO | 7,440 | +0,30 % | Jim Cramer on ImmunityBio: "That Stock Is Part of the Magical Thinking Era" | ||
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| ALDEYRA | 1,569 | -2,64 % | What's Going On With Aldeyra Therapeutics Stock On Thursday? | ||
| IOVANCE BIOTHERAPEUTICS | 3,261 | +0,98 % | Iovance Biotherapeutics: Aufsichtsratsmitglied Wendy Yarno kündigt Rücktritt an | ||
| GUARDANT HEALTH | 75,40 | +2,28 % | Cathie Wood's ARK sells Guardant Health stock, buys Arcturus Therapeutics | ||
| COHERUS ONCOLOGY | 1,349 | +2,94 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,958 | -1,94 % | EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug | ||
| ESPERION | 2,205 | +0,23 % | Esperion Therapeutics, Inc.: Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia | - Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,246 | -0,31 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| MACROGENICS | 2,426 | -1,78 % | MacroGenics, Inc.: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures | Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030... ► Artikel lesen |
ZENTALIS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,75 % bei einem Aktienkurs von 2,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.